Significant barriers to care for patients seeking medication for opioid use

Buprenorphine-naloxone (buprenorphine), a highly effective, evidence-based treatment for opioid use disorder (OUD), is difficult to access in states with high rates of death associated with OUD, according to new research led by Harvard T.H. Chan School of Public Health. The study also found that access to buprenorphine is especially challenging among patients with Medicaid coverage.

* This article was originally published here